In essence, “monomer” and “molecular building block” are two ways of describing the same class of substances in oligonucleotide chemistry. Both refer to the preassembled units used for chemical synthesis of oligonucleotide chains, namely phosphoramidite monomers. The term “molecular building block” is more common in medicinal chemistry and synthetic biology because it emphasizes the modular, engineerable nature of these compounds.
In oligonucleotide drug development, phosphoramidite monomers are increasingly treated as standardized molecular building blocks. Much like LEGO pieces, they can be assembled in a predetermined sequence to achieve precise structural control. Their basic categories include DNA monomers, RNA monomers, and modified monomers. Monomers corresponding to the natural building units of DNA and RNA can be classified as conventional oligo monomers, whereas monomers containing special functional groups are generally classified as modified oligo monomers.
Compared with conventional oligo monomers, modified monomers display much greater structural diversity. Below is an overview of conventional oligo monomers and the major structural types of modified oligo monomers.
Conventional and Modified Oligo Monomers
Conventional Oligo Monomers
Conventional oligo monomers are the standard phosphoramidite monomers used to construct natural DNA or RNA sequences. They provide the canonical nucleobases and sugar backbones required for routine oligonucleotide synthesis.
Modified Oligo Monomers
Modified oligo monomers contain additional functional groups or structural alterations that enable fluorescence labeling, affinity capture, terminal functionalization, base modification, or post-synthetic conjugation. These monomers are essential for expanding oligonucleotide functionality beyond native nucleic acid architecture.
Major Structural Types of Oligonucleotide Building Blocks
1. DMTrO–Modifier–Phosphoramidite
This is the most commonly used and most classical DNA synthesis monomer. Structurally, the 5′-hydroxyl is protected with a 4,4′-dimethoxytrityl (DMTrO-) group, which enables monitoring of synthesis efficiency through the color of the released DMT cation. The 3′-end carries a phosphoramidite reactive group, typically β-cyanoethyl N,N-diisopropyl phosphoramidite, which couples with the 5′-hydroxyl of the growing oligonucleotide chain in the presence of an activator. The modifier—such as a fluorescent dye, biotin, or amino group—is attached to the nucleoside base or sugar moiety through a stable linker, such as a C6 spacer.
Typical examples: 6-FAM, HEX, TET, VIC, Biotin, Digoxigenin
2. Modifier–Phosphoramidite
In this structure, the 5′-hydroxyl is not protected with DMTr. When used as the final monomer in chain assembly, the synthesized oligonucleotide ends with a free 5′-terminal modifier after synthesis, without requiring an additional deprotection step for terminal installation. This type is also useful for preparing oligonucleotides with special 5′-end structures or terminal functionalities.
Typical examples: 5′-Phosphate, 5′-Azide, 5′-Cholesterol
3. DMTrO–Modifier–CPG
This is the starting point of solid-phase oligonucleotide synthesis. In this format, controlled pore glass (CPG) serves as the solid support. The first nucleoside is attached to the support through a long-chain alkyl linker via its 3′-end, while its 5′-end remains protected by DMTr. The modifier is introduced on the base or sugar of that nucleoside. Oligonucleotide synthesis begins from this support and proceeds in the 5′ direction.
Typical examples: 3′-Biotin CPG, 3′-NH2 C7 CPG, 3′-6-FAM CPG
4. DMTrO–(dT–Modifier)–Phosphoramidite
This is a specialized standard phosphoramidite monomer in which the key feature is modification on the thymine base. Its overall architecture still follows the classic phosphoramidite design: a DMTr-protected 5′-end and a 3′-phosphoramidite reactive group. The distinguishing feature is that the modifier is introduced through the thymidine base, making this monomer especially useful for synthesizing oligonucleotides containing base-modified nucleotides.
Typical examples: Int Cy3 dT, Int ROX dT, Int BHQ1 dT
5. Modifier–NHS Ester
This is not a chain-extension monomer, but rather a labeling reagent used for post-synthetic modification. Its structure consists of a functional modifier linked to an N-hydroxysuccinimide (NHS) ester reactive group. NHS esters react efficiently and selectively with preinstalled primary amino groups on an oligonucleotide in mildly basic aqueous solution, forming stable amide bonds.
Typical examples: CY3 NHS Ester, CY5 NHS Ester, 6-FAM NHS Ester, Texas Red NHS Ester
Why Are Multiple Types of Modified Oligo Building Blocks Needed?
At first glance, if the goal is simply to introduce a modification, it may seem most straightforward to directly incorporate a DMTrO–Modifier–Phosphoramidite during synthesis. However, the existence of multiple structural types is driven by four core considerations: efficiency, cost, flexibility, and chemical feasibility. A useful analogy is to imagine oligonucleotide synthesis as customizing a special pearl necklace.
DMTrO–Modifier–Phosphoramidite: Predecorated Pearls
This type is like using pearls that already carry decorative elements. Its advantage is a standardized synthesis workflow. It can be inserted at virtually any internal position of the chain, making it highly suitable for site-specific internal modification. However, if the modifier is expensive or chemically fragile, each coupling step consumes a costly reagent and may expose the modifier to conditions that reduce its integrity. In addition, once incorporated, the position of the modifier is fixed.
Modifier–Phosphoramidite and DMTrO–Modifier–CPG: Precise End Positioning
These two formats are designed for accurate terminal installation. A 5′-modifier phosphoramidite functions like a terminal decorative clasp that is added as the final bead. A 3′-modifier CPG is like a preinstalled decorative base from which the necklace is built. Their key advantage is that the modifier is introduced directly at the desired chain end, avoiding additional terminal chemistry after synthesis. This improves efficiency and can reduce side reactions.
DMTrO–(dT–Modifier)–Phosphoramidite: Base-Specific Functionalization
This type is used when the modifier must be placed on the nucleobase itself, rather than at the terminus or along a linker. For functions that require base-level modification, such as the incorporation of nucleobase analogs or certain reporter groups, this strategy is often the only practical choice.
Why Is Post-Synthetic Labeling with Modifier–NHS Ester Still Essential?
Among all supplementary strategies, post-synthetic NHS ester labeling is one of the most important. Its major value lies in cost control, functional flexibility, and compatibility with sensitive or structurally complex modifiers.
1. Better Economy for Expensive or Fragile Modifiers
Direct synthesis with dye-bearing phosphoramidite monomers means that every labeling event consumes a full equivalent of an expensive modified monomer. In addition, the chemical environment of solid-phase synthesis may damage sensitive dyes or other labile groups.
By contrast, the NHS ester strategy first prepares a relatively inexpensive amino-modified oligonucleotide using affordable amino-functional monomers. The purified amino-containing oligonucleotide can then be reacted with an NHS-activated dye under mild aqueous conditions. This separates oligonucleotide assembly from delicate labeling chemistry and helps preserve sensitive modifiers.
Using the necklace analogy, instead of buying many costly pearls that already contain diamonds, one can first assemble a necklace with inexpensive hooked pearls, then attach the diamonds afterward. This is often more economical and gentler on the decorative element.
2. Much Greater Flexibility
The same amino-modified oligonucleotide backbone can be functionalized with different NHS esters depending on the application. For example, one batch may be labeled with CY3 NHS ester for fluorescence, while another may be conjugated with biotin NHS ester for capture or purification applications.
Likewise, if multiple amino handles are present, different labeling schemes can be designed to generate multi-labeled oligonucleotides. This degree of modularity is difficult to achieve with direct incorporation alone.
3. A Practical Solution for Modifiers That Cannot Be Introduced Directly
Some modifiers—especially large biomolecules, complex glycans, or highly sensitive functional groups—are not suitable for conversion into stable phosphoramidite monomers. In many cases, however, they can be introduced through post-synthetic conjugation chemistry using activated esters or related reactive intermediates. This makes the amino-handle-plus-NHS-labeling strategy a powerful workaround when direct phosphoramidite-based synthesis is chemically impractical.
Related Products and Services for Oligonucleotide Modification
We can provide a range of products and technical support closely related to oligonucleotide modification and phosphoramidite-based synthesis, including:
- Conventional DNA and RNA phosphoramidite monomers for standard oligonucleotide assembly
- Modified oligo phosphoramidites for fluorescent labeling, affinity tagging, amino functionalization, azide introduction, and other specialized applications
- Modified CPG supports for precise 3′-end functionalization
- NHS ester labeling reagents for post-synthetic conjugation of amino-modified oligonucleotides
- Custom oligonucleotide synthesis support for sequence-specific, terminal-specific, or internally modified oligos
- Tailored building block selection services to help match modification strategy with synthesis efficiency, cost, and downstream application needs
At BOC Sciences, we focus on providing reliable molecular building blocks and customization support for oligonucleotide research, labeling workflows, and nucleic acid-based therapeutic development.